This company has been marked as potentially delisted and may not be actively trading.

Chimerix (CMRX) Financials

Annual Income Statements for Chimerix

This table shows Chimerix's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-59	-117	-76	-71	-69	-113	-44	-173	172	-82	-88
Consolidated Net Income / (Loss)	-59	-117	-76	-71	-69	-113	-44	-173	172	-82	-88
Net Income / (Loss) Continuing Operations	-59	-117	-76	-71	-69	-113	-44	-173	172	-82	-88
Total Pre-Tax Income	-59	-117	-76	-71	-69	-113	-44	-173	172	-82	-88
Total Operating Income	-59	-118	-78	-72	-72	-116	-45	-173	-60	-93	-97
Total Gross Profit	4.04	11	5.70	4.49	7.22	13	5.37	1.98	33	0.32	0.21
Total Revenue	4.04	11	5.70	4.49	7.22	13	5.37	1.98	34	0.32	0.21
Operating Revenue	4.04	11	5.70	4.49	7.22	13	5.37	1.98	34	0.32	0.21
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.45	0.00	0.00
Operating Cost of Revenue	-	-	-	-	-	-	0.00	0.00	0.45	0.00	0.00
Total Operating Expenses	63	129	84	77	79	129	50	175	94	93	97
Selling, General & Admin Expense	18	31	25	27	24	21	14	19	22	25	22
Research & Development Expense	45	98	59	49	55	107	36	157	72	69	75
Total Other Income / (Expense), net	-0.45	0.88	1.56	1.12	2.13	3.41	0.99	0.16	233	11	8.18
Interest Expense	0.45	-0.88	-1.56	-1.12	-2.13	-3.41	-0.99	-0.16	-2.92	-11	-8.18
Other Income / (Expense), net	-	0.00	0.00	-	-	-	0.00	0.00	230	0.00	0.00
Income Tax Expense	-	-	-	-	-	-	0.00	0.00	0.04	0.00	0.00
Basic Earnings per Share	($1.80)	($2.67)	($1.65)	($1.51)	($1.43)	($2.03)	($0.70)	($2.04)	$1.97	($0.93)	($0.99)
Weighted Average Basic Shares Outstanding	33.00M	43.88M	46.27M	46.96M	48.59M	55.50M	62.18M	84.93M	87.56M	88.60M	89.70M
Diluted Earnings per Share	($1.80)	($2.67)	($1.65)	($1.51)	($1.43)	($2.03)	($0.70)	($2.04)	$1.94	($0.93)	($0.99)
Weighted Average Diluted Shares Outstanding	33.00M	43.88M	46.27M	46.96M	48.59M	55.50M	62.18M	84.93M	88.78M	88.60M	89.70M
Weighted Average Basic & Diluted Shares Outstanding	33.00M	43.88M	46.27M	46.96M	48.59M	55.50M	62.18M	87.03M	88.27M	89.21M	93.80M

This table shows Chimerix's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-23	241	-21	-21	-19	-24	-18	-22	-21	-23	-23
Consolidated Net Income / (Loss)	-23	241	-21	-21	-19	-24	-18	-22	-21	-23	-23
Net Income / (Loss) Continuing Operations	-23	241	-21	-21	-19	-24	-18	-22	-21	-23	-23
Total Pre-Tax Income	-23	242	-21	-21	-19	-24	-18	-22	-21	-23	-23
Total Operating Income	-23	12	-24	-24	-21	-27	-21	-24	-23	-25	-25
Total Gross Profit	0.44	32	0.81	0.28	0.03	0.01	0.00	0.00	0.13	0.03	0.06
Total Revenue	0.44	33	0.81	0.28	0.03	0.01	0.00	0.00	0.13	0.03	0.06
Operating Revenue	0.44	33	0.81	0.28	0.03	0.01	0.00	0.00	0.13	0.03	0.06
Total Operating Expenses	24	21	25	25	21	27	21	24	23	25	25
Selling, General & Admin Expense	5.84	5.31	5.35	5.68	4.45	9.30	5.17	5.55	4.53	5.17	6.95
Research & Development Expense	18	15	19	19	17	17	16	19	18	20	18
Total Other Income / (Expense), net	-0.02	230	2.74	2.85	2.77	2.70	2.65	2.52	2.15	1.91	1.60
Interest Expense	0.02	-0.20	-2.74	-2.85	-2.77	-2.70	-2.65	-2.52	-2.15	-1.91	-1.60
Basic Earnings per Share	($0.27)	$2.75	($0.23)	($0.24)	($0.21)	($0.27)	($0.21)	($0.25)	($0.23)	($0.26)	($0.25)
Weighted Average Basic Shares Outstanding	87.44M	87.63M	87.56M	88.29M	88.58M	88.62M	88.60M	89.26M	89.63M	89.70M	89.70M
Diluted Earnings per Share	($0.27)	$2.75	($0.26)	($0.24)	($0.21)	($0.27)	($0.21)	($0.25)	($0.23)	($0.26)	($0.25)
Weighted Average Diluted Shares Outstanding	87.44M	87.81M	88.78M	88.29M	88.58M	88.62M	88.60M	89.26M	89.63M	89.70M	89.70M
Weighted Average Basic & Diluted Shares Outstanding	87.62M	88.05M	88.27M	88.58M	88.58M	88.89M	89.21M	89.63M	89.64M	89.94M	93.80M

This table details how cash moves in and out of Chimerix's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	18	-108	31	-33	63	-64	30	-32	10	1.82	3.39
Net Cash From Operating Activities	-47	-100	-64	-50	-54	-75	-36	-100	-47	-69	-75
Net Cash From Continuing Operating Activities	-47	-100	-64	-50	-54	-75	-36	-100	-47	-69	-75
Net Income / (Loss) Continuing Operations	-59	-117	-76	-71	-69	-113	-44	-173	172	-82	-88
Consolidated Net Income / (Loss)	-59	-117	-76	-71	-69	-113	-44	-173	172	-82	-88
Depreciation Expense	0.28	0.66	1.06	1.09	0.86	0.56	0.40	0.17	0.10	0.09	0.09
Amortization Expense	1.32	1.69	1.22	-0.01	-0.85	-1.92	-0.20	1.15	-1.32	-6.96	-3.47
Non-Cash Adjustments To Reconcile Net Income	4.41	13	16	17	14	45	5.55	70	-214	17	9.47
Changes in Operating Assets and Liabilities, net	6.22	2.36	-5.93	2.49	1.94	-5.97	1.73	2.29	-3.42	2.42	7.44
Net Cash From Investing Activities	-160	-169	94	16	105	11	65	-44	70	71	71
Net Cash From Continuing Investing Activities	-160	-169	94	16	105	11	65	-44	70	71	71
Purchase of Property, Plant & Equipment	-1.02	-2.39	-0.84	-0.15	-0.18	-0.16	-0.06	-0.21	-0.07	-0.09	-0.29
Purchase of Investments	-211	-295	-103	-163	-132	-168	-74	-115	-241	-129	-131
Sale of Property, Plant & Equipment	-	-	-	-	0.00	0.00	0.01	0.00	0.00	0.01	0.00
Divestitures	-	-	-	-	-	-	0.00	0.00	234	0.00	0.00
Sale and/or Maturity of Investments	52	128	198	179	237	178	139	71	77	199	203
Net Cash From Financing Activities	225	161	0.61	0.78	11	0.35	1.41	112	-13	0.31	7.05
Net Cash From Continuing Financing Activities	225	161	0.61	0.78	11	0.35	1.41	112	-13	0.31	7.05
Repayment of Debt	-5.70	-4.69	-	-	-	-	0.00	0.00	-14	-0.16	-0.40
Issuance of Common Equity	226	163	0.44	0.71	11	0.33	0.43	109	0.86	0.47	7.44
Other Financing Activities, net	4.60	3.11	0.17	0.12	0.12	0.04	0.99	3.83	0.61	0.00	0.01

This table details how cash moves in and out of Chimerix's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-3.87	246	-248	-9.89	4.15	-5.98	14	-8.64	-3.37	7.99	7.40
Net Cash From Operating Activities	-11	7.13	-20	-22	-14	-18	-15	-18	-18	-21	-19
Net Cash From Continuing Operating Activities	-11	7.13	-20	-22	-14	-18	-15	-17	-18	-21	-19
Net Income / (Loss) Continuing Operations	-23	241	-21	-21	-19	-24	-18	-22	-21	-23	-23
Consolidated Net Income / (Loss)	-23	241	-21	-21	-19	-24	-18	-22	-21	-23	-23
Depreciation Expense	0.02	0.03	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.03
Amortization Expense	0.07	0.06	-1.60	-2.05	-1.86	-1.61	-1.44	-1.12	-1.13	-0.79	-0.44
Non-Cash Adjustments To Reconcile Net Income	3.59	-226	4.17	4.36	2.96	7.88	2.25	2.75	2.19	2.38	2.14
Changes in Operating Assets and Liabilities, net	9.22	-8.47	-1.62	-3.19	3.11	-0.24	2.74	2.72	1.89	0.75	2.07
Net Cash From Investing Activities	6.70	238	-228	12	19	12	28	8.68	14	28	20
Net Cash From Continuing Investing Activities	6.70	238	-228	12	19	12	28	8.68	14	28	20
Purchase of Property, Plant & Equipment	-	-0.07	0.00	-0.06	-0.01	-0.02	-	-0.03	-0.07	-0.03	-0.16
Purchase of Investments	-	-6.05	-230	-6.80	-39	-51	-32	-41	-24	-30	-36
Sale and/or Maturity of Investments	6.70	10	1.35	19	57	63	60	50	39	58	56
Net Cash From Financing Activities	-0.01	0.78	-0.03	0.20	-0.03	0.08	0.06	0.21	-0.04	0.18	6.71
Net Cash From Continuing Financing Activities	-0.01	0.78	-0.03	0.20	-0.03	0.08	0.06	0.21	-0.04	0.18	6.71
Repayment of Debt	-	-	-0.19	-0.16	-0.03	-0.03	0.06	-0.17	-0.04	-0.04	-0.14
Issuance of Common Equity	-	0.30	-	0.36	-	0.11	-	0.38	-	0.22	6.84
Other Financing Activities, net	-	0.51	-	-	-	-	-	-	-	-	0.01

This table presents Chimerix's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	292	356	287	235	191	119	85	101	279	213	146
Total Current Assets	237	229	236	157	189	118	82	96	228	189	136
Cash & Equivalents	128	21	51	19	81	17	47	15	26	28	31
Short-Term Investments	106	200	181	133	105	97	32	73	191	155	101
Accounts Receivable	0.11	2.43	1.60	1.68	0.33	1.23	0.34	0.00	1.04	0.00	0.06
Prepaid Expenses	2.78	6.07	2.85	3.33	2.60	3.39	2.36	4.68	9.76	6.27	4.25
Plant, Property, & Equipment, net	1.31	3.05	2.84	1.89	1.21	0.54	0.21	0.25	0.23	0.22	0.42
Total Noncurrent Assets	53	124	47	77	0.05	0.74	2.85	4.48	51	23	9.64
Long-Term Investments	53	124	47	77	-	-	0.00	2.02	49	22	8.48
Other Noncurrent Operating Assets	0.14	0.07	0.06	0.07	0.05	0.74	2.85	2.46	2.35	1.78	1.17
Total Liabilities & Shareholders' Equity	292	356	287	235	191	119	85	101	279	213	146
Total Liabilities	17	21	11	13	13	9.42	11	32	22	20	24
Total Current Liabilities	17	20	10	13	13	9.23	8.53	30	20	18	24
Accounts Payable	5.94	10	3.89	3.81	4.69	2.40	1.28	2.79	3.03	2.85	3.94
Accrued Expenses	6.83	9.72	6.22	9.38	8.28	6.83	7.25	13	17	16	20
Total Noncurrent Liabilities	0.18	0.35	0.44	0.22	0.14	0.20	2.81	2.39	2.07	1.30	0.46
Other Noncurrent Operating Liabilities	0.18	-	0.44	0.22	0.14	0.20	2.81	2.39	2.07	1.30	0.46
Total Equity & Noncontrolling Interests	275	335	276	222	178	110	73	68	257	193	122
Total Preferred & Common Equity	275	335	276	222	178	110	73	68	257	193	122
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	275	335	276	222	178	110	73	68	257	193	122
Common Stock	497	676	692	710	734	779	786	954	971	989	1,006
Retained Earnings	-222	-339	-416	-487	-556	-669	-712	-886	-713	-796	-884
Accumulated Other Comprehensive Income / (Loss)	0.04	-0.76	-0.44	-0.96	-0.09	0.04	0.00	-0.02	-0.34	0.01	0.02

This table presents Chimerix's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	54	294	259	241	225	194	179	159
Total Current Assets	51	291	225	212	201	163	153	141
Cash & Equivalents	28	274	16	20	14	19	16	24
Short-Term Investments	15	10	199	186	180	140	133	113
Accounts Receivable	-	0.47	0.67	0.03	0.01	0.00	0.13	0.16
Prepaid Expenses	3.85	6.02	9.33	5.74	6.14	4.00	5.16	4.52
Plant, Property, & Equipment, net	0.21	0.25	0.27	0.26	0.25	0.26	0.28	0.28
Total Noncurrent Assets	2.59	2.51	34	29	24	31	25	17
Long-Term Investments	0.00	0.00	31	27	23	29	23	16
Other Noncurrent Operating Assets	2.59	2.51	2.19	2.05	1.90	1.61	1.47	1.28
Total Liabilities & Shareholders' Equity	54	294	259	241	225	194	179	159
Total Liabilities	26	20	18	17	17	20	23	23
Total Current Liabilities	23	18	16	15	16	19	22	22
Accounts Payable	1.74	3.28	2.85	1.82	2.50	3.82	4.16	5.34
Accrued Expenses	17	14	14	14	13	15	18	17
Total Noncurrent Liabilities	2.36	2.22	1.79	1.63	1.47	1.01	0.83	0.64
Other Noncurrent Operating Liabilities	2.11	1.97	1.79	1.63	1.47	1.01	0.83	0.64
Total Equity & Noncontrolling Interests	28	274	240	224	208	174	156	136
Total Preferred & Common Equity	28	274	240	224	208	174	156	136
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	28	274	240	224	208	174	156	136
Common Stock	962	966	975	978	986	992	994	996
Retained Earnings	-934	-692	-735	-753	-777	-817	-838	-861
Accumulated Other Comprehensive Income / (Loss)	-0.07	-0.04	-0.23	-0.81	-0.63	-0.18	-0.21	0.26

This table displays calculated financial ratios and metrics derived from Chimerix's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-7.55%	166.39%	-47.02%	-21.19%	60.57%	73.49%	-57.09%	-63.16%	1,609.15%	-99.04%	-34.57%
EBITDA Growth	-65.99%	-102.42%	34.72%	6.15%	-0.82%	-63.89%	62.23%	-288.30%	197.66%	-159.46%	-0.02%
EBIT Growth	-67.19%	-100.88%	34.08%	7.50%	0.69%	-61.98%	61.62%	-289.52%	197.63%	-154.98%	-3.76%
NOPAT Growth	-105.69%	-100.88%	34.08%	7.50%	0.69%	-61.98%	61.62%	-289.52%	50.26%	-7.90%	-3.76%
Net Income Growth	-62.74%	-97.89%	34.92%	7.08%	2.13%	-62.04%	61.34%	-298.04%	199.38%	-147.68%	-7.66%
EPS Growth	50.68%	-48.33%	38.20%	8.48%	5.30%	-41.96%	65.52%	-191.43%	195.10%	-147.94%	-6.45%
Operating Cash Flow Growth	-84.19%	-111.80%	36.00%	21.45%	-7.18%	-39.94%	52.07%	-177.29%	53.10%	-47.41%	-8.52%
Free Cash Flow Firm Growth	7.11%	-141.45%	26.92%	21.64%	-0.86%	-81.77%	66.40%	-308.37%	50.01%	-5.69%	3.45%
Invested Capital Growth	-448.85%	-3.46%	64.06%	-101.03%	-38.58%	60.53%	-58.56%	-45.67%	-11.87%	-25.93%	-60.86%
Revenue Q/Q Growth	7.36%	22.18%	-16.54%	-2.94%	71.97%	17.93%	-51.25%	-35.18%	2.32%	-71.43%	33.33%
EBITDA Q/Q Growth	-25.76%	-18.29%	23.07%	-5.34%	3.85%	8.96%	-20.33%	-19.24%	322.46%	3.07%	-2.91%
EBIT Q/Q Growth	-26.27%	-17.95%	22.67%	-4.82%	4.36%	9.05%	-21.52%	-19.07%	322.44%	3.13%	-4.03%
NOPAT Q/Q Growth	-26.27%	-17.95%	22.67%	-4.82%	4.36%	9.05%	-21.52%	-19.07%	20.67%	3.13%	-4.03%
Net Income Q/Q Growth	-25.56%	-17.63%	23.05%	-6.42%	5.81%	9.23%	-23.12%	-19.13%	12.07%	3.30%	-5.73%
EPS Q/Q Growth	-109.55%	-12.18%	23.96%	-5.59%	7.14%	9.78%	-20.69%	-12.09%	8.38%	5.10%	-4.21%
Operating Cash Flow Q/Q Growth	-27.27%	-19.18%	26.68%	-5.09%	6.64%	6.04%	-18.30%	-33.33%	23.05%	7.25%	-6.66%
Free Cash Flow Firm Q/Q Growth	-5.69%	-23.18%	22.86%	-2.60%	8.16%	3.01%	-12.73%	-18.21%	17.12%	8.99%	-6.33%
Invested Capital Q/Q Growth	-32.98%	8.09%	-50.85%	-51.91%	-86.81%	26.10%	-21.54%	-35.46%	12.71%	-31.97%	-10.74%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	98.68%	100.00%	100.00%
EBITDA Margin	-1,417.33%	-1,077.01%	-1,327.01%	-1,580.24%	-992.20%	-937.27%	-824.98%	-8,695.60%	496.86%	-30,842.59%	-47,143.87%
Operating Margin	-1,457.08%	-1,098.78%	-1,367.10%	-1,604.41%	-992.31%	-926.46%	-828.67%	-8,762.00%	-178.53%	-28,723.77%	-45,550.47%
EBIT Margin	-1,457.08%	-1,098.78%	-1,367.10%	-1,604.41%	-992.31%	-926.46%	-828.67%	-8,762.00%	500.48%	-28,723.77%	-45,550.47%
Profit (Net Income) Margin	-1,468.12%	-1,090.62%	-1,339.71%	-1,579.53%	-962.78%	-899.24%	-810.16%	-8,753.71%	509.01%	-25,337.96%	-41,691.98%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	99.98%	100.00%	100.00%
Interest Burden Percent	100.76%	99.26%	98.00%	98.45%	97.02%	97.06%	97.77%	99.91%	101.72%	88.21%	91.53%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.02%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-31.79%	-38.48%	-24.98%	-28.51%	-34.79%	-78.30%	-47.48%	-244.64%	105.91%	-36.50%	-56.17%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-29.05%	-36.50%	-24.26%	-27.63%	-33.62%	-74.81%	-43.62%	-187.19%	89.12%	-37.82%	-53.83%
Return on Assets (ROA)	-29.27%	-36.23%	-23.77%	-27.20%	-32.62%	-72.61%	-42.65%	-187.02%	90.64%	-33.36%	-49.27%
Return on Common Equity (ROCE)	-31.79%	-38.48%	-24.98%	-28.51%	-34.79%	-78.30%	-47.48%	-244.64%	105.91%	-36.50%	-56.17%
Return on Equity Simple (ROE_SIMPLE)	-21.60%	-34.99%	-27.66%	-32.00%	-39.12%	-102.39%	-59.31%	-253.82%	67.03%	-42.53%	-72.64%
Net Operating Profit after Tax (NOPAT)	-41	-83	-55	-50	-50	-81	-31	-121	-60	-65	-68
NOPAT Margin	-1,019.96%	-769.15%	-956.97%	-1,123.08%	-694.62%	-648.52%	-580.07%	-6,133.40%	-178.49%	-20,106.64%	-31,885.33%
Net Nonoperating Expense Percent (NNEP)	-9.45%	-11.02%	-7.00%	-8.08%	-9.33%	-20.92%	-12.85%	-66.76%	135.85%	-7.21%	-12.07%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-23.50%	-33.75%	-55.55%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.32%	0.00%	0.00%
SG&A Expenses to Revenue	433.84%	290.80%	438.57%	604.09%	326.80%	169.10%	254.21%	943.51%	65.43%	7,592.90%	10,474.06%
R&D to Revenue	1,123.24%	907.98%	1,028.53%	1,100.31%	765.51%	857.36%	674.46%	7,918.49%	211.78%	21,230.86%	35,176.42%
Operating Expenses to Revenue	1,557.08%	1,198.78%	1,467.10%	1,704.41%	1,092.31%	1,026.46%	928.67%	8,862.00%	277.21%	28,823.77%	45,650.47%
Earnings before Interest and Taxes (EBIT)	-59	-118	-78	-72	-72	-116	-45	-173	169	-93	-97
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-57	-116	-76	-71	-72	-117	-44	-172	168	-100	-100
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.35	1.23	0.77	0.98	0.73	1.13	4.12	8.18	0.64	0.44	2.57
Price to Tangible Book Value (P/TBV)	5.35	1.23	0.77	0.98	0.73	1.13	4.12	8.18	0.64	0.44	2.57
Price to Revenue (P/Rev)	363.49	38.38	37.36	48.55	18.07	9.95	56.31	282.23	4.84	264.07	1,476.31
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.95	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	105.13%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	293.38	6.38	0.00	0.00	0.00	0.89	41.62	243.63	0.00	0.00	815.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.21	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.03	-1.03	-1.02	-1.02	-1.04	-1.04	-1.05	-1.10	-1.05	-1.05	-1.10
Leverage Ratio	1.09	1.06	1.05	1.05	1.07	1.08	1.11	1.31	1.17	1.09	1.14
Compound Leverage Factor	1.09	1.05	1.03	1.03	1.03	1.05	1.09	1.31	1.19	0.96	1.04
Debt to Total Capital	1.54%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	17.02%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	1.54%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	17.02%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	98.46%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	82.98%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.08	0.00	0.00	0.00	0.00	0.00	0.00	-0.08	0.00	0.00	0.00
Net Debt to EBITDA	4.95	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.10	0.00	0.00	0.00	0.00	0.00	0.00	-0.12	0.00	0.00	0.00
Net Debt to NOPAT	6.87	0.00	0.00	0.00	0.00	0.00	0.00	0.63	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	50.29	10.37	10.16	6.60	1.79	-1.92	3.59	-6.84	3.81	-3.11	-2.02
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	13.91	11.34	23.40	11.86	14.61	12.80	9.57	3.20	11.18	10.25	5.70
Quick Ratio	13.75	11.04	23.12	11.61	14.41	12.43	9.29	2.96	10.70	9.91	5.52
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-34	-82	-60	-47	-48	-87	-29	-119	-59	-63	-61
Operating Cash Flow to CapEx	-4,624.46%	-4,166.65%	-7,587.99%	-33,195.36%	-29,682.32%	-47,582.91%	-75,079.17%	-48,275.36%	-66,009.86%	-85,293.83%	-26,124.39%
Free Cash Flow to Firm to Interest Expense	-76.59	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-105.55	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-107.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.03	0.02	0.02	0.03	0.08	0.05	0.02	0.18	0.00	0.00
Accounts Receivable Turnover	22.82	8.48	2.83	2.74	7.17	16.02	6.83	0.00	0.00	0.62	6.95
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	4.90	4.94	1.94	1.90	4.65	14.31	14.25	8.48	140.93	1.44	0.66
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.15	0.00	0.00
Days Sales Outstanding (DSO)	15.99	43.04	129.02	133.24	50.89	22.79	53.44	0.00	0.00	588.06	52.51
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2,376.99	0.00	0.00
Cash Conversion Cycle (CCC)	15.99	43.04	129.02	133.24	50.89	22.79	53.44	0.00	-2,376.99	588.06	52.51
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-8.62	-8.92	-3.20	-6.44	-8.93	-3.52	-5.59	-8.14	-9.10	-11	-18
Invested Capital Turnover	-0.79	-1.23	-0.94	-0.93	-0.94	-2.01	-1.18	-0.29	-3.92	-0.03	-0.01
Increase / (Decrease) in Invested Capital	-7.05	-0.30	5.71	-3.24	-2.49	5.40	-2.06	-2.55	-0.97	-2.36	-6.98
Enterprise Value (EV)	1,185	69	-66	-10	-56	11	224	482	-102	-119	173
Market Capitalization	1,469	413	213	218	130	125	303	559	164	86	313
Book Value per Share	$7.53	$7.27	$5.96	$4.71	$3.50	$1.79	$1.17	$0.79	$2.92	$2.17	$1.35
Tangible Book Value per Share	$7.53	$7.27	$5.96	$4.71	$3.50	$1.79	$1.17	$0.79	$2.92	$2.17	$1.35
Total Capital	279	335	276	222	178	110	73	82	257	193	122
Total Debt	4.30	0.00	0.00	0.00	0.00	0.00	0.00	14	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-283	-344	-279	-228	-187	-113	-79	-76	-266	-204	-140
Capital Expenditures (CapEx)	1.02	2.39	0.84	0.15	0.18	0.16	0.05	0.21	0.07	0.08	0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.89	-12	-5.66	-8.18	-10	-4.61	-5.84	-8.46	-9.61	-12	-20
Debt-free Net Working Capital (DFNWC)	225	209	226	143	176	109	73	80	208	171	112
Net Working Capital (NWC)	220	209	226	143	176	109	73	66	208	171	112
Net Nonoperating Expense (NNE)	18	35	22	21	19	31	12	52	-233	17	21
Net Nonoperating Obligations (NNO)	-283	-344	-279	-228	-187	-113	-79	-76	-266	-204	-140
Total Depreciation and Amortization (D&A)	1.61	2.34	2.29	1.09	0.01	-1.35	0.20	1.31	-1.23	-6.87	-3.38
Debt-free, Cash-free Net Working Capital to Revenue	-244.80%	-108.49%	-99.28%	-182.09%	-139.11%	-36.82%	-108.66%	-427.39%	-28.41%	-3,755.56%	-9,227.83%
Debt-free Net Working Capital to Revenue	5,561.53%	1,938.84%	3,969.84%	3,189.52%	2,445.84%	869.60%	1,361.22%	4,037.85%	614.13%	52,675.00%	52,867.92%
Net Working Capital to Revenue	5,455.20%	1,938.84%	3,969.84%	3,189.52%	2,445.84%	869.60%	1,361.22%	3,330.42%	614.13%	52,675.00%	52,867.92%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.80)	($2.67)	($1.65)	($1.51)	($1.43)	($2.03)	($0.70)	($2.04)	$1.97	($0.93)	($0.99)
Adjusted Weighted Average Basic Shares Outstanding	41.09M	46.18M	46.56M	47.65M	50.90M	61.74M	85.68M	84.93M	87.56M	88.60M	89.70M
Adjusted Diluted Earnings per Share	($1.80)	($2.67)	($1.65)	($1.51)	($1.43)	($2.03)	($0.70)	($2.04)	$1.94	($0.93)	($0.99)
Adjusted Weighted Average Diluted Shares Outstanding	41.09M	46.18M	46.56M	47.65M	50.90M	61.74M	85.68M	84.93M	88.78M	88.60M	89.70M
Adjusted Basic & Diluted Earnings per Share	($1.80)	($2.67)	($1.65)	($1.51)	($1.43)	($2.03)	($0.70)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	33.00M	43.88M	46.27M	46.96M	48.59M	55.50M	62.18M	87.03M	88.27M	89.21M	93.80M
Normalized Net Operating Profit after Tax (NOPAT)	-41	-83	-55	-50	-50	-81	-31	-121	-60	-65	-68
Normalized NOPAT Margin	-1,019.96%	-769.15%	-956.97%	-1,123.08%	-694.62%	-648.52%	-580.07%	-6,133.40%	-178.49%	-20,106.64%	-31,885.33%
Pre Tax Income Margin	-1,468.12%	-1,090.62%	-1,339.71%	-1,579.53%	-962.78%	-899.24%	-810.16%	-8,753.71%	509.11%	-25,337.96%	-41,691.98%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-131.99	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-92.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-134.27	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-94.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-0.08%	-0.58%	-0.02%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Chimerix's official financial filings.

Metric	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	12.53%	30,325.23%	1,669.57%	1,786.67%	-94.09%	-99.97%	-99.51%	-100.00%	396.15%	136.36%	1,325.00%
EBITDA Growth	-35.33%	1,419.55%	35.43%	-6.70%	0.70%	-111.71%	12.47%	2.89%	-3.23%	9.60%	-12.33%
EBIT Growth	-31.61%	1,397.40%	39.76%	2.23%	8.95%	-111.06%	12.61%	-0.71%	-6.95%	7.10%	-17.98%
NOPAT Growth	-31.61%	189.39%	39.76%	2.23%	8.95%	-260.52%	12.61%	-0.71%	-6.95%	7.10%	-17.98%
Net Income Growth	-32.12%	1,400.44%	46.93%	13.71%	20.85%	-109.94%	13.35%	-2.33%	-11.35%	4.62%	-26.39%
EPS Growth	-28.57%	1,409.52%	36.59%	14.29%	22.22%	-109.82%	19.23%	-4.17%	-9.52%	3.70%	-19.05%
Operating Cash Flow Growth	17.00%	146.62%	41.25%	5.21%	-35.81%	-351.59%	27.02%	21.18%	-23.30%	-14.36%	-32.08%
Free Cash Flow Firm Growth	7.39%	238.34%	37.49%	2.17%	-151.43%	-227.18%	22.27%	46.87%	56.51%	54.02%	16.36%
Invested Capital Growth	-127.79%	-73.60%	-11.87%	-8.12%	39.08%	16.71%	-25.93%	-143.95%	-78.63%	-91.70%	-60.86%
Revenue Q/Q Growth	2,833.33%	7,298.86%	-97.50%	-65.23%	-90.81%	-57.69%	-63.64%	-100.00%	0.00%	-79.85%	119.23%
EBITDA Q/Q Growth	5.07%	1,133.74%	-110.52%	-3.37%	11.65%	-21.93%	21.40%	-15.15%	6.08%	-6.78%	2.34%
EBIT Q/Q Growth	5.35%	1,129.20%	-109.87%	-1.70%	11.85%	-25.02%	22.03%	-17.20%	6.39%	-8.59%	0.97%
NOPAT Q/Q Growth	5.35%	170.91%	-243.23%	-1.70%	11.85%	-25.02%	22.03%	-17.20%	6.39%	-8.59%	0.97%
Net Income Q/Q Growth	5.24%	1,128.47%	-108.68%	-1.97%	13.08%	-29.12%	24.29%	-20.42%	5.41%	-10.61%	-0.33%
EPS Q/Q Growth	3.57%	1,118.52%	-109.45%	7.69%	12.50%	-28.57%	22.22%	-19.05%	8.00%	-13.04%	3.85%
Operating Cash Flow Q/Q Growth	54.96%	167.50%	-380.42%	-11.19%	35.47%	-25.04%	18.65%	-20.09%	-0.94%	-15.98%	6.05%
Free Cash Flow Firm Q/Q Growth	51.35%	295.49%	-197.78%	-5.19%	-25.03%	1.12%	40.23%	28.10%	-2.34%	-4.54%	-8.74%
Invested Capital Q/Q Growth	-174.17%	28.64%	12.71%	36.69%	-54.47%	2.43%	-31.97%	-22.65%	-13.11%	-4.71%	-10.74%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	98.98%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%
EBITDA Margin	-5,307.27%	741.51%	-3,119.16%	-9,274.20%	-89,184.62%	-257,027.27%	-555,575.00%	0.00%	-18,555.81%	-98,303.85%	-43,792.98%
Operating Margin	-5,328.86%	35.77%	-2,925.55%	-8,557.60%	-82,107.69%	-242,627.27%	-520,250.00%	0.00%	-17,699.22%	-95,357.69%	-43,073.68%
EBIT Margin	-5,328.86%	741.26%	-2,925.55%	-8,557.60%	-82,107.69%	-242,627.27%	-520,250.00%	0.00%	-17,699.22%	-95,357.69%	-43,073.68%
Profit (Net Income) Margin	-5,333.64%	741.40%	-2,574.94%	-7,551.94%	-71,446.15%	-218,054.55%	-454,025.00%	0.00%	-16,034.88%	-87,996.15%	-40,270.18%
Tax Burden Percent	100.00%	99.94%	99.44%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	100.09%	100.08%	88.51%	88.25%	87.02%	89.87%	87.27%	89.66%	90.60%	92.28%	93.49%
Effective Tax Rate	0.00%	0.06%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-144.54%	81.17%	105.91%	121.87%	143.19%	-35.21%	-36.50%	-39.86%	-44.62%	-48.59%	-56.17%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-32.35%	114.69%	-520.97%	-1,800.63%	-18,769.67%	-1,059.94%	-685.05%	0.00%	-12.15%	-78.98%	-50.90%
Return on Assets (ROA)	-32.38%	114.71%	-458.54%	-1,589.02%	-16,332.46%	-952.59%	-597.84%	0.00%	-11.01%	-72.88%	-47.59%
Return on Common Equity (ROCE)	-144.54%	81.17%	105.91%	121.87%	143.19%	-35.21%	-36.50%	-39.86%	-44.62%	-48.59%	-56.17%
Return on Equity Simple (ROE_SIMPLE)	-380.60%	56.08%	0.00%	73.06%	80.52%	-40.76%	0.00%	-47.44%	-54.44%	-61.57%	0.00%
Net Operating Profit after Tax (NOPAT)	-16	12	-17	-17	-15	-19	-15	-17	-16	-17	-17
NOPAT Margin	-3,730.20%	35.75%	-2,047.89%	-5,990.32%	-57,475.38%	-169,839.09%	-364,175.00%	0.00%	-12,389.46%	-66,750.38%	-30,151.58%
Net Nonoperating Expense Percent (NNEP)	-8.39%	116.32%	-2.51%	-2.95%	-2.64%	-2.12%	-1.53%	-2.21%	-2.33%	-2.99%	-3.35%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-6.49%	-	-	-	-7.55%	-	-	-	-14.12%
Cost of Revenue to Revenue	0.00%	1.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	1,327.27%	16.32%	656.88%	2,006.71%	17,107.69%	84,581.82%	129,250.00%	0.00%	3,513.95%	19,896.15%	12,198.25%
R&D to Revenue	4,101.59%	46.88%	2,368.67%	6,650.88%	65,100.00%	158,145.45%	391,100.00%	0.00%	14,285.27%	75,561.54%	30,975.44%
Operating Expenses to Revenue	5,428.86%	63.20%	3,025.55%	8,657.60%	82,207.69%	242,727.27%	520,350.00%	0.00%	17,799.22%	95,457.69%	43,173.68%
Earnings before Interest and Taxes (EBIT)	-23	241	-24	-24	-21	-27	-21	-24	-23	-25	-25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-23	241	-25	-26	-23	-28	-22	-25	-24	-26	-25
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.51	0.62	0.64	0.46	0.48	0.41	0.44	0.54	0.50	0.61	2.57
Price to Tangible Book Value (P/TBV)	6.51	0.62	0.64	0.46	0.48	0.41	0.44	0.54	0.50	0.61	2.57
Price to Revenue (P/Rev)	299.12	5.12	4.84	3.26	3.18	74.98	264.07	2,306.41	545.25	524.30	1,476.31
Price to Earnings (P/E)	0.00	1.10	0.95	0.63	0.59	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	90.84%	105.13%	157.84%	168.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	229.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	815.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.14	-1.04	-1.05	-1.04	-1.09	-1.04	-1.05	-1.05	-1.07	-1.07	-1.10
Leverage Ratio	1.36	1.13	1.17	1.12	1.17	1.08	1.09	1.09	1.11	1.12	1.14
Compound Leverage Factor	1.36	1.13	1.03	0.99	1.02	0.97	0.95	0.98	1.00	1.03	1.07
Debt to Total Capital	0.89%	0.09%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.89%	0.09%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.11%	99.91%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.40	3.76	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.57	3.74	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-20.97	5.73	1.53	0.47	0.24	-1.23	-1.99	-2.58	-4.06	-5.03	-0.39
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.18	16.44	11.18	13.68	13.79	12.94	10.25	8.61	6.94	6.33	5.70
Quick Ratio	1.84	16.10	10.70	13.11	13.41	12.54	9.91	8.40	6.71	6.13	5.52
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-8.21	16	-16	-17	-21	-20	-12	-8.78	-8.98	-9.39	-10
Operating Cash Flow to CapEx	0.00%	9,900.00%	0.00%	-35,846.77%	-119,516.67%	-119,553.33%	0.00%	-64,881.48%	-24,905.63%	-78,876.92%	-11,820.86%
Free Cash Flow to Firm to Interest Expense	-391.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-502.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-502.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.15	0.18	0.21	0.23	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	126.89	0.00	0.00	0.00	4.73	0.62	0.12	1.86	1.92	6.95
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.42	128.12	140.93	137.47	146.11	4.54	1.44	0.15	0.54	0.60	0.66
Accounts Payable Turnover	0.07	0.18	0.15	0.11	0.19	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	2.88	0.00	0.00	0.00	77.09	588.06	2,977.87	196.44	190.53	52.51
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	5,122.81	2,071.60	2,376.99	3,475.17	1,954.34	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	-5,122.81	-2,068.72	-2,376.99	-3,475.17	-1,954.34	77.09	588.06	2,977.87	196.44	190.53	52.51
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-15	-10	-9.10	-5.76	-8.90	-8.69	-11	-14	-16	-17	-18
Invested Capital Turnover	-0.06	-4.02	-3.92	-6.15	-2.86	-0.12	-0.03	0.00	-0.01	-0.01	-0.01
Increase / (Decrease) in Invested Capital	-8.20	-4.42	-0.97	-0.43	5.71	1.74	-2.36	-8.30	-7.00	-7.97	-6.98
Enterprise Value (EV)	139	-115	-102	-135	-126	-132	-119	-94	-93	-69	173
Market Capitalization	182	169	164	111	107	85	86	95	79	83	313
Book Value per Share	$0.32	$3.13	$2.92	$2.72	$2.53	$2.35	$2.17	$1.95	$1.74	$1.51	$1.35
Tangible Book Value per Share	$0.32	$3.13	$2.92	$2.72	$2.53	$2.35	$2.17	$1.95	$1.74	$1.51	$1.35
Total Capital	28	274	257	240	224	208	193	174	156	136	122
Total Debt	0.25	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.25	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-43	-284	-266	-246	-233	-217	-204	-188	-171	-152	-140
Capital Expenditures (CapEx)	0.00	0.07	-0.00	0.06	0.01	0.02	-0.00	0.03	0.07	0.03	0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15	-11	-9.61	-6.43	-9.58	-9.36	-12	-15	-17	-18	-20
Debt-free Net Working Capital (DFNWC)	27	273	208	208	196	185	171	144	131	119	112
Net Working Capital (NWC)	27	273	208	208	196	185	171	144	131	119	112
Net Nonoperating Expense (NNE)	7.06	-230	4.29	4.42	3.63	5.30	3.59	4.80	4.70	5.52	5.77
Net Nonoperating Obligations (NNO)	-43	-284	-266	-246	-233	-217	-204	-188	-171	-152	-140
Total Depreciation and Amortization (D&A)	0.10	0.08	-1.58	-2.03	-1.84	-1.58	-1.41	-1.10	-1.11	-0.77	-0.41
Debt-free, Cash-free Net Working Capital to Revenue	-2,515.13%	-33.94%	-28.41%	-18.87%	-28.45%	-825.66%	-3,755.56%	-36,417.07%	-11,677.78%	-11,051.57%	-9,227.83%
Debt-free Net Working Capital to Revenue	4,522.86%	827.11%	614.13%	611.05%	582.50%	16,323.81%	52,675.00%	351,456.10%	91,217.36%	74,627.67%	52,867.92%
Net Working Capital to Revenue	4,522.86%	827.11%	614.13%	611.05%	582.50%	16,323.81%	52,675.00%	351,456.10%	91,217.36%	74,627.67%	52,867.92%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.27)	$2.75	($0.23)	($0.24)	($0.21)	($0.27)	($0.21)	($0.25)	($0.23)	($0.26)	($0.25)
Adjusted Weighted Average Basic Shares Outstanding	87.44M	87.63M	87.56M	88.29M	88.58M	88.62M	88.60M	89.26M	89.63M	89.70M	89.70M
Adjusted Diluted Earnings per Share	($0.27)	$2.75	($0.26)	($0.24)	($0.21)	($0.27)	($0.21)	($0.25)	($0.23)	($0.26)	($0.25)
Adjusted Weighted Average Diluted Shares Outstanding	87.44M	87.81M	88.78M	88.29M	88.58M	88.62M	88.60M	89.26M	89.63M	89.70M	89.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	87.62M	88.05M	88.27M	88.58M	88.58M	88.89M	89.21M	89.63M	89.64M	89.94M	93.80M
Normalized Net Operating Profit after Tax (NOPAT)	-16	12	-17	-17	-15	-19	-15	-17	-16	-17	-17
Normalized NOPAT Margin	-3,730.20%	35.75%	-2,047.89%	-5,990.32%	-57,475.38%	-169,839.09%	-364,175.00%	0.00%	-12,389.46%	-66,750.38%	-30,151.58%
Pre Tax Income Margin	-5,333.64%	741.87%	-2,589.31%	-7,551.94%	-71,446.15%	-218,054.55%	-454,025.00%	0.00%	-16,034.88%	-87,996.15%	-40,270.18%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-1,116.52	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-781.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-1,116.52	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-781.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Chimerix (NASDAQ:CMRX) Financial Overview (Q2 2022 to Q4 2024)

Chimerix continues to operate with significant net losses each quarter over the past two and a half years, reflecting its stage as a clinical-stage biopharmaceutical company investing heavily in R&D. Here's a review of key financial trends and data points for investors interested in the company's recent performance:

Despite operating losses, Chimerix has maintained substantial liquidity with cash, equivalents, and short-term investments totaling around $140 million as of Q3 2024.
The company consistently invests heavily in research & development, showing commitment to progressing its drug pipeline, with R&D expenses exceeding $15 million to $19 million quarterly in recent periods.
Operating expenses have been managed relatively consistently around $20 million to $25 million per quarter, with SG&A generally below $7 million.
Total revenue remains minimal, generally under $0.15 million per quarter in 2024, a typical scenario for a clinical-stage biopharma company without commercial products.
Amortization expense varies quarter to quarter, generally around $1 million, which is a non-cash charge.
Interest expense has been declining from over $2.7 million in early 2023 to below $1.6 million by Q4 2024, relieving financial burden slightly.
The company has posted continuous net losses each quarter, ranging approximately from -$18 million to -$24 million, with no profitable quarter during this period.
Operating income consistently negative by over $20 million per quarter indicates that operating costs far exceed any revenue generated.
Cash flows from operations are negative each quarter, typically in the range of -$14 million to -$20 million, reflecting ongoing cash burn.
Total assets have decreased from over $290 million in mid-2022 to approximately $159 million by Q3 2024, mainly due to use of cash and investments over time.
Total equity has declined from over $270 million in early 2022 down to about $136 million by Q3 2024, reflecting accumulated losses.

Summary: Chimerix remains a typical clinical-stage biotech, heavily investing in R&D with minimal revenues and continuous net losses. Their cash reserves are still substantial enough to support continuing operations, but the company is burning cash at a steady rate. Investors should be aware of the ongoing need for funding and the risks involved in the clinical development process. Positive signs include controlled SG&A expenses and decreasing interest costs, but profitability and revenue growth have yet to materialize.

09/19/25 06:45 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Chimerix's Financials

When does Chimerix's fiscal year end?

According to the most recent income statement we have on file, Chimerix's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Chimerix's net income changed over the last 10 years?

Chimerix's net income appears to be on a downward trend, with a most recent value of -$88.39 million in 2024, rising from -$59.31 million in 2014. The previous period was -$82.10 million in 2023. See Chimerix's forecast for analyst expectations on what’s next for the company.

What is Chimerix's operating income?

Chimerix's total operating income in 2024 was -$96.57 million, based on the following breakdown:

Total Gross Profit: $212 thousand
Total Operating Expenses: $96.78 million

How has Chimerix's revenue changed over the last 10 years?

Over the last 10 years, Chimerix's total revenue changed from $4.04 million in 2014 to $212 thousand in 2024, a change of -94.8%.

How much debt does Chimerix have?

Chimerix's total liabilities were at $24.33 million at the end of 2024, a 23.2% increase from 2023, and a 41.1% increase since 2014.

How much cash does Chimerix have?

In the past 10 years, Chimerix's cash and equivalents has ranged from $15.40 million in 2021 to $128.46 million in 2014, and is currently $31.05 million as of their latest financial filing in 2024.

How has Chimerix's book value per share changed over the last 10 years?

Over the last 10 years, Chimerix's book value per share changed from 7.53 in 2014 to 1.35 in 2024, a change of -82.0%.

Related Companies

This page (NASDAQ:CMRX) was last updated on 9/19/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chimerix (CMRX) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Chimerix's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Chimerix (CMRX) Financials

Annual Income Statements for Chimerix

Quarterly Income Statements for Chimerix

Annual Cash Flow Statements for Chimerix

Quarterly Cash Flow Statements for Chimerix

Annual Balance Sheets for Chimerix

Quarterly Balance Sheets for Chimerix

Annual Metrics And Ratios for Chimerix

Quarterly Metrics And Ratios for Chimerix

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Chimerix's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools